

Science Based Targets Initiative Approves Astellas' Greenhouse Gas Reduction Plan

TOKYO, November 5, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the company's mid-to-long term greenhouse gas (GHG) emission reduction targets to achieve the "2 degrees Celsius target" of the Paris Agreement were approved by the Science Based Targets (SBT) Initiative¹ as a science-based international initiative.

As a company dedicated to improving the health of people around the world, Astellas recognizes that addressing environmental issues including climate change is an important management issue. In order to contribute to the development of a sustainable society, Astellas is working to reduce GHG emissions and improve energy efficiency. As part of these efforts, in order to contribute to the achievement of the targets of the Paris Agreement, Astellas established new GHG emission reduction targets that cover all business activities in its Environmental Action Plan from the current fiscal year ending March 31, 2019. Accordingly, the SBT Initiative has recently approved our targets as a science-based target.

Astellas' targets are as follows:

- Astellas commits to reduce absolute Scope² 1 and 2 GHG emissions 30% by 2030 from a 2015 base-year
- Astellas also commits to reduce Scope 3 GHG emissions 20% per JPY of revenue by 2030 from a 2015 base-year.

Astellas will continue to identify opportunities to address global environmental issues, such as climate change, in the future.

(1) **Science Based Targets (SBT) initiative:** Jointly established in 2015 by four organizations: the CDP, the United Nations Global Compact, the World Resources Institute, and the World Nature Conservation Fund, an international initiative to encourage companies and national governments to set GHG reduction targets to achieve the “2 degrees Celsius target”, as agreed under the Paris Agreement of 2015.

(2) **Scope:** Range of calculation of GHG emissions

Scope 1: Direct emissions of GHG from fuels used in-house

Scope 2: Indirect emissions of GHG from consumption of purchased electricity

Scope 3: Emissions of GHG in the supply chain of business activities, such as raw materials procurement and product use

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473